Forward Pharma Receives Decision to Grant From EPO for DMF Patent in Europe
This projected European patent is one of several elements of the Company's intellectual property, which also includes three U.S. pending patent applications and two other European pending patent applications covering methods of treating multiple sclerosis with formulations that provide a 480 mg daily dose of DMF.
"This would be our first issued patent covering the use of 480 mg per day of DMF in MS and is further evidence of the progress we are making with our intellectual property estate," commented
The EPO examiner allowed our 480 mg patent claims after considering third party observations both requesting the EPO to not grant the application as well as suspend its examination. Biogen markets Tecfidera®, a product containing DMF as the active ingredient for the treatment of MS at a daily dose of 480 mg. Tecfidera® was approved by the
EP2801355 is one of several avenues through which
Additional information on the projected EP2801355 patent, including the decision to grant, is available by accessing the European Patent Office website, register.epo.org. Additional information on the Company's U.S. patent applications is available by accessing the Patent Application Information Retrieval (PAIR) website http://pair.uspto.gov/.
Our principal executive offices are located at Østergade 24A, 1, 1100 Copenhagen K,
Forward Pharma A/S Media Contact:
Forward Looking Statements:
Certain statements in this press release may constitute "forward-looking statements" of the Company within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements which contain language such as "believe," "expect," "anticipate," "hope," "would" and "potential." Forward-looking statements are predictions only which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed in such statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: the Company's ability to obtain, maintain and defend issued patents with protective claims; the issuance and term of term of patents; the commencement of any patent interference or infringement action; the Company's ability to prevail in or obtain a favorable decision in any such action; the Company's ability to recover damages in any such action; uncertainties relating to our development plans and activities, including the results, timing, cost and location thereof; risks and uncertainties related to the scope, validity and enforceability of our intellectual property rights in general and the impact on us of patents and other intellectual property right of third parties. These and other factors are identified and described in detail in certain of our filings with the